Tag Archives: Dexcom

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Infinity Pharma (NASDAQ: INFI) and Orasure Technologies (NASDAQ: OSUR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dexcom (DXCM – Research Report), Infinity Pharma (INFI – Research Report) and Orasure Technologies (OSUR – Research Report) with bullish sentiments. Dexcom

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Centene (NYSE: CNC) and Blueprint Medicines (NASDAQ: BPMC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dexcom (DXCM – Research Report), Centene (CNC – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments. Dexcom (DXCM)

BTIG Maintains a Hold Rating on Dexcom (DXCM)

BTIG analyst Marie Thibault maintained a Hold rating on Dexcom (DXCM – Research Report) today. The company’s shares closed last Tuesday at $313.53, close to its 52-week high of $344.55. According to TipRanks.com, Thibault is a 3-star analyst with an

Morgan Stanley Remains a Hold on Dexcom (DXCM)

Morgan Stanley analyst David Lewis maintained a Hold rating on Dexcom (DXCM – Research Report) today and set a price target of $278.00. The company’s shares closed last Monday at $262.63. According to TipRanks.com, Lewis is a 4-star analyst with

Dexcom (DXCM) Received its Third Buy in a Row

After Oppenheimer and Canaccord Genuity gave Dexcom (NASDAQ: DXCM) a Buy rating last month, the company received another Buy, this time from Merrill Lynch. Analyst Travis Steed reiterated a Buy rating on Dexcom yesterday and set a price target of

Oppenheimer Sticks to Its Buy Rating for Dexcom (DXCM)

In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $285.00. The company’s shares closed last Monday at $252.21, close to its 52-week high of $254.70.